CDK4 and interstitial lung disease: A Japanese study reported an even higher incidence of CDK4/6i-induced ILD than previously documented in the PALOMA and MONARCH trials, with ILD occurring in 8.0% of patients (13% of abemaciclib-treated cases and 6.5% of palbociclib-treated cases), and a median onset time of approximately six months [20].